Steven Schulman, MD
Cardiovascular Disease · Baltimore, MDNPI 1912922667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 59.6% of the total. Reporting peaked in 2019 at $70 and has fallen 72.3% since, to $19 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in MD, where the typical reported total is $1,418.
Across 7 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$115
- Amgen$45
- Chiesi USA, Inc.$33
Across 4 payments — averaging $189,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$749K
- Novartis$11K
What the payments were for
- Food & beverage$193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $115 |
| Amgen | 3 | $45 |
| Chiesi USA, Inc. | 2 | $33 |
How this compares
$193 in reported general payments places this provider in the 20th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $98,269 |
| EntrestoSacubitril/Valsartan | 19 | $25,854 |
| JardianceEmpagliflozin | 11 | $19,494 |
| Repatha SureclickEvolocumab | 20 | $12,693 |
| Metoprolol Succinate | 63 | $873 |
| Rosuvastatin Calcium | 48 | $789 |
| Ezetimibe | 40 | $757 |
| Enalapril Maleate | 16 | $467 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $378 |
| Atorvastatin Calcium | 41 | $368 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 27 | $359 |
| Spironolactone | 70 | $330 |
| Lisinopril | 40 | $328 |
| Losartan Potassium | 57 | $318 |
| Chlorthalidone | 20 | $293 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.